Sign in

    Ed White

    Research Analyst at H.C. Wainwright

    Edward White is Managing Director and Senior Biotechnology Analyst at H.C. Wainwright & Co., specializing in equity research focused on small to mid-cap biotechnology and healthcare companies. He covers over 65 stocks, including Cullinan Oncology, Silverback Therapeutics, Mirati Therapeutics, and Chimerix, with a career success rate of 35% and an average return per rating of -1.6%, earning notable recognition for individual recommendations such as an 800% return on Chimerix. White began his analyst career in 1996, holding roles at Fahnestock, BMO Capital Markets, Deutsche Bank Securities, Mitsubishi UFJ Trust (VP/Healthcare Equity Analyst managing $1.3 billion), Murphy & Durieu, and FBR before joining H.C. Wainwright in 2017. He holds FINRA certifications in Series 7, 63, 86, and 87, an MBA in Finance from Rensselaer Polytechnic Institute, and a BS in Biology from Manhattan College.

    Ed White's questions to Inhibikase Therapeutics (IKT) leadership

    Ed White's questions to Inhibikase Therapeutics (IKT) leadership • Q2 2024

    Question

    Ed White asked for clarification on what the company wants to see in the November top-line data for risvodetinib to proceed to Phase III, the planned patient numbers for the Phase III trials, expectations for the IkT-001Pro IND clearance, and any potential gating factors or delays for starting the PAH trial.

    Answer

    Milton Werner stated that for the risvodetinib data, any positive trend on disease assessments or biomarkers after 12 weeks would provide robust support to proceed to Phase III, which is planned for 300-400 patients total across two trials. For the IkT-001Pro trial, gearing up is expected to take 9-12 months, and the primary gating factor is securing adequate capital, as current funds are insufficient for a trial of that scale.

    Ask Fintool Equity Research AI

    Ed White's questions to CMRX leadership

    Ed White's questions to CMRX leadership • Q2 2024

    Question

    Asked about the timing of ONC206 safety/PK data release, the ex-U.S. commercial strategy for dordaviprone (especially Australia), and the timeline and nature of launch-related spending.

    Answer

    Management stated that ONC206 safety and PK data should be available in the months following the end-of-year dose escalation completion, ahead of efficacy data. For Australia, they are progressing through the regulatory process and exploring a lean commercial model. Launch-related spending will increase modestly in late 2024 and more significantly in 2025, with a gated approach focused on planning and stakeholder engagement.

    Ask Fintool Equity Research AI

    Ed White's questions to TCON leadership

    Ed White's questions to TCON leadership • Q4 2023

    Question

    Asked about the revised timeline for final ENVASARC data, potential new deals and pricing for the product development platform (PDP), and the company's cash runway and expense outlook. The questions were asked by Steve on behalf of Ed White.

    Answer

    The final ENVASARC data is now expected in the second half of 2024 (Q3) to allow for a 6-month duration of response assessment for all patients. While specific PDP deals were not disclosed, the company outlined two monetization strategies: platform licensing and replacing CROs for partners. The cash runway extends to mid-2024, with expenses decreasing and potential for future income-positive quarters from PDP deals.

    Ask Fintool Equity Research AI